Another anti-TIGIT mAb, tiragolumab, was tested in a phase 2 trial in combination with atezolizumab in chemotherapy-naive patients with locally advanced PD-L1-selected NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.